Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04884282

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) — COMBI-TED  

Metastatic Non Small Cell Lung Cancer Clinical Trial

Official title:
A Multicenter, Phase II, Open Label, Randomized Trial Evaluating the Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

Clinical Trial Summary

This is a phase II, non-comparative, randomized study assessing combination of Tedopi with docetaxel or with nivolumab in NSCLC patients failing after first- line chemoimmunotherapy. In this non-comparative study, the standard arm (arm C) will serve as a calibration arm. All NSCLC patients candidate for second- line therapy are considered eligible for the study if they are HLA-A2+ and if they progressed after at least 4 cycles of previous first-line chemo-immunotherapy. After evaluation of all inclusion and exclusion criteria and after informed consent signature, all eligible patients will be treated with Tedopi plus docetaxel (arm A) or Tedopi plus nivolumab (arm B) or docetaxel as single agent (arm C- standard arm). Docetaxel therapy will be given until disease progression, unacceptable toxicity or patient refusal, and up to maximum 6 cycles. Tedopi or nivolumab will be given until disease progression, unacceptable toxicity or patient refusal.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04884282
Study type Interventional
Source Fondazione Ricerca Traslazionale
Contact Federico Cappuzzo, MD
Phone +39 06.5266.5698
Email f.cappuzzo@gmail.com
Status Recruiting
Phase Phase 2
Start date October 12, 2021
Completion date May 17, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04965090 - A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT06060613 - Safety and Efficacy of OBX-115 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05236608 - A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC Phase 1/Phase 2
Recruiting NCT04614103 - Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer Phase 2
Not yet recruiting NCT06066138 - A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Phase 1
Recruiting NCT05215340 - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations Phase 3
Withdrawn NCT06068153 - AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC Phase 2
Recruiting NCT05429320 - A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT05478538 - Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Completed NCT01773109 - Etirinotecan Pegol (NKTR-102) in NSCLC Phase 2
Recruiting NCT04743505 - Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Recruiting NCT05111197 - Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy Phase 3
Recruiting NCT05555732 - Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Phase 3
Recruiting NCT05676749 - C-TIL051 in Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT05566223 - CISH Inactivated TILs in the Treatment of NSCLC Phase 1/Phase 2
Terminated NCT01060514 - Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer Phase 1
Completed NCT05167500 - Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment
Recruiting NCT05259319 - Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) Phase 1
Enrolling by invitation NCT04697446 - External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Completed NCT04511533 - Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations Phase 4